Gilead Sciences, Inc.

1320 articles with Gilead Sciences, Inc.

• Gilead Receives Approval in Canada for BIKTARVY™ (bictegravir, emtricitabine, tenofovir alafenamide) for the Treatment of HIV-1 Infection

  7/12/2018

  In clinical trials, BIKTARVY demonstrated high efficacy, and a high barrier to resistance

• 

  Allogene Therapeutics Announces the Formation of its Scientific Advisory Board

  7/10/2018

  Allogene Therapeutics announced the implementation of its Scientific Advisory Board (SAB). The SAB is made up of five leaders in oncology, immunology, drug discovery and development, and will consult on strategic and scientific matters.

• Michael Amoroso to Join Kite as Senior Vice President and Head of Worldwide Commercial, Cell Therapy

  7/9/2018

  Mr. Amoroso Brings Significant Expertise in Oncology to New Role

• 

  Seattle Cancer Care Alliance One of Only 51 Centers Certified for CAR-T Therapy

  7/9/2018

  Because of the potential for significant side effects of CAR-T therapies, the FDA requires Risk Evaluation and Mitigation Strategies (REMS) programs. The Bezos Family Immunotherapy Clinic at the Seattle Cancer Care Alliance is one of those approved sites.
• 

  Is Gilead Poised for a Comeback?

  7/6/2018

  Gilead may be down, but at least one analyst thinks the company is poised for a turnaround.
• 

  Cowen Research Report: Ignore Equity Analysts in Terms of Biotech Stocks

  7/3/2018

  Cowen Research’s biotech team published a recent report and concluded that investors would have better luck ignoring—or even doing the complete opposite—of what equity analysts advise.

• European CHMP Adopts Positive Opinion for Yescarta® (axicabtagene ciloleucel) for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy

  6/29/2018

  Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the company’s Marketing Authorization Application (MAA) for Yescarta® (axicabtagene ciloleucel)

• 

  Netherlands Biopharma Landscape Expected to Grow With the Arrival of the EMA

  6/27/2018

  As the European Medicines Agency prepares to make Amsterdam its new home following the U.K.’s Brexit, Holland is likely to see its biopharma industry snag a hoped-for boost in new business due to the presence of the regulatory agency.
• 

  Akero Therapeutics Launches with $65 Million Series A to Battle NASH

  6/25/2018

  Akero Therapeutics, headquartered in Cambridge, Massachusetts, closed on a $65 million Series A financing round.
• 

  Allogene Expands Leadership Team, Taps Cowen Senior Analyst as New CFO

  6/19/2018

  Since Allogene Therapeutics launched in April the company has been rapidly expanding its leadership team as it drives forward with a mission of developing allogeneic CAR-T therapies.
• 

  With Headway in NASH, Madrigal Pharma is Considering Sale

  6/14/2018

  Reportedly, Madrigal Pharmaceuticals is considering a sale. After receiving interest from other big drug companies, the nine-employee company is evaluating its options.
• 

  First International NASH Day is a Call to Action

  6/12/2018

  The prevalence of nonalcoholic steatohepatitis (NASH) is increasing across the globe and is expected to be the leading indication for liver transplants by 2020. Despite that, awareness of the disease is somewhat low.
• 

  Metacrine Closes $65 Million Series C Round

  6/6/2018

  Metracrine, based in San Diego, completed a Series C financing round worth $65 million.
• 

  Hookipa Biotech and Gilead Ink Deal to Develop HIV and Hepatitis B Therapies

  6/5/2018

  Hookipa Biotech and Gilead inked a research collaboration deal to develop and commercialize therapeutics for hepatitis B (HBV) and HIV.

• Hookipa and Gilead Enter into a Collaboration and License Agreement to Develop Immunotherapies Against HIV and Hepatitis B

  6/5/2018

  Hookipa and Gilead will jointly develop therapeutics against HIV and Hepatitis B infections; Hookipa and Gilead will jointly research and Hookipa will manufacture arenavirus-based vectors for clinical development by Gilead

• Kite Announces New Data Analyses for CAR T Therapy in Patients with Blood Cancers at the 2018 American Society of Clinical Oncology Meeting

  6/4/2018

  Kite, a Gilead Company announced new analyses from the ZUMA chimeric antigen receptor T (CAR T) cell therapy development program that are being presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

• Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors

  6/4/2018

  Kite, a Gilead Company (Nasdaq: GILD), announced results from an ongoing Phase 1 study conducted by the National Cancer Institute (NCI) showing that clinical responses were observed with investigational T cell receptor (TCR) cell therapy targeting human papillomavirus type 16 (HPV-16) E7 in solid tumor cancers caused by HPV.

• Gilead Sciences Announces Leadership Changes in Corporate Development and Strategy

  6/4/2018

  Gilead Sciences, Inc. announced the promotion of Andrew Dickinson to Executive Vice President, Corporate Development and Strategy.

• 

  Primary Endpoint Hit: Gilead and Galapagos’ JAK1 Inhibitor for Arthritis Positive in Phase II

  5/31/2018

  Gilead Sciences and its development partner Galapagos NV announced positive data from its Phase II EQUATOR trial of filgotinib in psoriatic arthritis.

• Gilead Sciences to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13

  5/30/2018

  Gilead Sciences, Inc. announced that Robin L. Washington, Gilead’s Executive Vice President and Chief Financial Officer, and John McHutchison, Gilead’s Chief Scientific Officer and Head of Research & Development, will participate in a fireside chat at the Goldman Sachs 39th Annual Global Healthcare Conference.